Personalis, Inc. (PSNL) Misses Q3 EPS by 29c, Beats on Revenue
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Personalis Reports Third Quarter 2024 Financial Results
November 6, 2024 4:01 PM EST41% Year-over-Year Increase in Revenue Driven by Strong Biopharma Growth of 96%
Raising 2024 Revenue Guidance Due to Accelerating Growth
Cash Balance of $143.7 Million Extends Expected Runway Into First-Half of 2027
FREMONT, Calif.--(BUSINESS WIRE)-- Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the third quarter ended September 30, 2024, and provided recent business accomplishments.
Recent Business Accomplishments
Raised approximately $35.0 million in net financing proceeds from Tempus AI,... More